Integrated safety in tocilizumab clinical trials

Area of Science:

• Rheumatology
• Immunology
• Clinical Pharmacology

Background:

• Tocilizumab's efficacy and safety in rheumatoid arthritis (RA) were established in phase 3 trials.
• Patients from these trials transitioned to open-label extension studies for long-term evaluation.
• This analysis reports the pooled long-term safety profile of tocilizumab.

Purpose of the Study:

• To evaluate the long-term safety of tocilizumab in patients with rheumatoid arthritis.
• To analyze cumulative safety data from multiple clinical trials, including extension studies.
• To assess adverse event rates and identify any trends with prolonged tocilizumab exposure.

Main Methods:

• Pooled safety data from five core phase 3 trials, two extension trials, and one clinical pharmacology study were analyzed.
• Data included an all-control population (n=4,199) and an all-exposed population (n=4,009) receiving at least one dose of tocilizumab.
• Safety data were collected up to February 6, 2009, with a total exposure of 8,580 patient-years.

Main Results:

• Overall adverse event (AE) and serious AE (SAE) rates were 278.2/100 PY and 14.4/100 PY, respectively.
• Specific SAEs included serious infections (4.7/100 PY), gastrointestinal perforations (0.28/100 PY), and malignancies (1.1/100 PY).
• Rates of SAEs and serious infections remained stable over time, with no increase noted during prolonged exposure.

Conclusions:

• The long-term safety profile of tocilizumab (mean 2.4 years) is consistent with findings from shorter-term phase 3 studies (up to 1 year).
• Tocilizumab exhibits a stable safety profile with extended treatment duration in rheumatoid arthritis patients.